CD4 and pulmonary fibrosis: Guideline-discordant erlotinib rechallenge accelerated lymphocyte depletion, culminating in high-grade CMV viremia with CD4+ lymphocytopenia (0.16×109/L) and irreversible pulmonary fibrosis despite ganciclovir-induced virologic clearance.